Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
T Schlothauer, S Herter, CF Koller… - Protein Engineering …, 2016 - academic.oup.com
Recombinant human IgG antibodies (hIgGs) completely devoid of binding to Fcγ receptors
(FcγRs) and complement protein C1q, and thus with abolished immune effector functions …
(FcγRs) and complement protein C1q, and thus with abolished immune effector functions …
[HTML][HTML] Engineering an IgG scaffold lacking effector function with optimized developability
FW Jacobsen, R Stevenson, C Li… - Journal of Biological …, 2017 - ASBMB
IgG isotypes can differentially bind to Fcγ receptors and complement, making the selection of
which isotype to pursue for development of a particular therapeutic antibody important in …
which isotype to pursue for development of a particular therapeutic antibody important in …
An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations
O Vafa, GL Gilliland, RJ Brezski, B Strake, T Wilkinson… - Methods, 2014 - Elsevier
Abstract The Fc variant of IgG2, designated as IgG2σ, was engineered with
V234A/G237A/P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ …
V234A/G237A/P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ …
[HTML][HTML] High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields, AK Namenuk, K Hong, YG Meng… - Journal of Biological …, 2001 - ASBMB
Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated
immune responses with cellular effector functions. A high resolution map of the binding site …
immune responses with cellular effector functions. A high resolution map of the binding site …
[HTML][HTML] IgGA: a “cross-isotype” engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions
All clinically approved antibodies are of the IgG isotype and mediate the clearance of target
cells via binding to Fcγ receptors and complement (C1q). Even though IgA can elicit …
cells via binding to Fcγ receptors and complement (C1q). Even though IgA can elicit …
Engineering therapeutic antibodies for improved function
LG Presta, RL Shields, AK Namenuk… - Biochemical Society …, 2002 - portlandpress.com
The binding sites on human IgG1 for human Fcγ receptor (FcγR) I, FcγRIIa, FcγRIIb, FcγRIIIa
and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding …
and neonatal FcR have been mapped. A common set of IgG1 residues is involved in binding …
Harnessing Fc receptor biology in the design of therapeutic antibodies
P Sondermann, DE Szymkowski - Current opinion in immunology, 2016 - Elsevier
Highlights•The antibody Fc domain engages immune-activating, inhibitory, and homeostatic
Fc receptors.•Fc domains are largely unaltered in existing therapeutic antibodies, whether to …
Fc receptors.•Fc domains are largely unaltered in existing therapeutic antibodies, whether to …
[HTML][HTML] Fc-engineered antibodies with immune effector functions completely abolished
I Wilkinson, S Anderson, J Fry, LA Julien, D Neville… - PLoS …, 2021 - journals.plos.org
Elimination of the binding of immunoglobulin Fc to Fc gamma receptors (FcγR) is highly
desirable for the avoidance of unwanted inflammatory responses to therapeutic antibodies …
desirable for the avoidance of unwanted inflammatory responses to therapeutic antibodies …
IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions
CH Lee, G Romain, W Yan, M Watanabe… - Nature …, 2017 - nature.com
Engineered crystallizable fragment (Fc) regions of antibody domains, which assume a
unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide …
unique and unprecedented asymmetric structure within the homodimeric Fc polypeptide …
Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131
F Mimoto, H Katada, S Kadono, T Igawa… - … , Design & Selection, 2013 - academic.oup.com
Abstract Engaging inhibitory FcγRIIb by Fc region has been recently reported to be an
attractive approach for improving the efficacy of antibody therapeutics. However, the …
attractive approach for improving the efficacy of antibody therapeutics. However, the …